Viewing Study NCT04385368


Ignite Creation Date: 2025-12-24 @ 5:36 PM
Ignite Modification Date: 2025-12-25 @ 3:07 PM
Study NCT ID: NCT04385368
Status: COMPLETED
Last Update Posted: 2024-08-30
First Post: 2020-04-30
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
Sponsor: AstraZeneca
Organization: